High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis

• Authors: Martin Malý , Ivana Hadačová , Petr Hájek , David Zemánek , Josef Veselka
• Languages of publication: EN

Abstracts

EN

High-residual platelet activity despite the dual antiplatelet treatment with aspirin and clopidogrel is associated with major adverse cardiac events, including stent thrombosis. Acute and subacute stent thrombosis is rare, but presents itself with serious complications including high mortality and morbidity rates. Light transmittance aggregometry with specific agonists - arachidonic acid and 5-adenosin diphosphate - is still considered a standard for the assessment of platelet reactivity, besides novel methods like vasodilator-stimulated phosphoprotein phosphorylation. In our case study, we report the coincidence of high-residual platelet activity with subacute stent thrombosis despite the recommended doses of antiplatelet agents - aspirin and clopidogrel. Stent thrombosis was treated by aspiration thrombectomy, and antiplatelet treatment was modified by increasing the dose of aspirin and substituting clopidogrel with a firstgeneration thienopyridin - ticlopidin. The effect of the treatment was documented by reaching the optimal inhibition of platelet reactivity. In the 6- and 12-month follow-up, the patient presented no ischemic events.

Keywords

EN

Resistance; Dual antiplatelet therapy; Stent thrombosis; Light transmittance aggregometry; Clopidogrel

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 1
• Pages: 119-124

Dates

published

1 - 3 - 2009

online

11 - 2 - 2009

Contributors

author

Martin Malý

• CardioVascular Center, Department of Cardiology, University Hospital Motol, 1st Medical Faculty, 150 00, Prague, Czech Republic

author

Ivana Hadačová

• Department of Hematology, University Hospital Motol, 150 00, Prague, Czech Republic

author

Petr Hájek

• CardioVascular Center, Department of Cardiology, University Hospital Motol, 1st Medical Faculty, 150 00, Prague, Czech Republic

author

David Zemánek

• CardioVascular Center, Department of Cardiology, University Hospital Motol, 1st Medical Faculty, 150 00, Prague, Czech Republic

author

Josef Veselka

• CardioVascular Center, Department of Cardiology, University Hospital Motol, 1st Medical Faculty, 150 00, Prague, Czech Republic

References

• [1] Park S.J., Lee S.W., Optimal management of platelet function after coronary stenting., Curr. Treat. Options. Cardiovasc. Med., 2007, 9, 37–45 http://dx.doi.org/10.1007/s11936-007-0049-7[Crossref]
• [2] Bonello L., Camoin-Jau L., Arques S., Boyer C.H., Panagides D., Wittenberg O., et al., Adjusted clopidogrel loading doses according to Vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major averse cardiovascular events in patiens with clopidogrel resistence., J. Am. Coll. Cardiol., 2008, 14, 1404–11 http://dx.doi.org/10.1016/j.jacc.2007.12.044[Crossref]
• [3] Gum P.A., Mottle-Marchant K., Welsh P.A., White J., Topol E.J., A prospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease., J. Am. Coll. Cardiol., 2003, 41, 961–5 http://dx.doi.org/10.1016/S0735-1097(02)03014-0[Crossref]
• [4] Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al., Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study., J. Am. Coll. Cardiol., 2005, 46, 1820–1826 http://dx.doi.org/10.1016/j.jacc.2005.07.041[Crossref]
• [5] Regar E., Lemos P.A., Saia F., Degertekin M., Tanabe K., Lee C.H., et al., Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients., Am. J. Cardiol., 2004, 93, 1271–75 http://dx.doi.org/10.1016/j.amjcard.2004.02.013[Crossref]
• [6] Cutlip D.E., Baim D.S., Ho K.K., Popma J.J., Lansky A.J., Cohen D.J., et al., Stent thrombosis in the modern area: pooled analysis of multicenter coronary stent clinical trials., Circulation., 2001, 103, 1967–71 [Crossref]
• [7] Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al., Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study., J. Am. Coll. Cardiol., 2005, 46, 1827–32 http://dx.doi.org/10.1016/j.jacc.2005.07.056[Crossref]
• [8] Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A., Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention., J. Am. Coll. Cardiol., 2007, 49, 657–66 http://dx.doi.org/10.1016/j.jacc.2006.10.050[Crossref]
• [9] Watala C., Chudzik A., Tchorzewski H., Gwozdzinski K., Impaired action of nitric oxide on blood platelets in premature newborns., Arch. Med. Sci., 2008, 4, 315–323
• [10] Boncler M., Gresner P., Nocun M., Rywaniak J., Dolnik M., Rysz J., Wilk R., Czyz M., Markuszewski L., Banach M., Watala C., Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation., Biochim. Biophys. Acta., 2007, 1770, 1651–9 [WoS][Crossref]
• [11] Veselka J., Zemánek D., Duchoňová R., Blaško P., Adla T., Tesař D., Neuwirth J., Coronary angiography and dual-source computed tomography are complementary methods in diagnosis of significant stenosis of the right coronary artery originating from the left aortic sinus., Cent. Eur. J. Med., 2008, 3,111–114 http://dx.doi.org/10.2478/s11536-007-0053-z[Crossref][WoS]
• [12] Colombo A., Hall P., Nakamura S., Almagor Y., Maiello L., Martini G., et al., Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance., Circulation., 1995, 91, 1676–88 [Crossref]
• [13] Hall P., Nakamura S., Maiello L., Itoh A., Blengino S., Martini G., et al., A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation., Circulation., 1996, 93, 215–22 [Crossref]
• [14] Moussa I., Di Mario C., Reimers B., Akiyama T., Tobis J., Colombo A., Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome., J. Am. Coll. Cardiol., 1997, 29, 6–12 http://dx.doi.org/10.1016/S0735-1097(96)00452-4[Crossref]
• [15] Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al., Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction., Circulation., 2004, 109, 3171–75 http://dx.doi.org/10.1161/01.CIR.0000130846.46168.03[Crossref]
• [16] Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al., Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation., Catheter. Cardiovasc. Interv., 2003, 59, 295–302 http://dx.doi.org/10.1002/ccd.10497[Crossref]
• [17] Gurbel P.A., Bliden K.P., Hiatt B.L., O’Connor C.M., Clopidogrel for coronary stenting: response variability, drug resistance and the effect of pretreatment platelet reactivity., Circulation., 2003, 107, 2908–13 http://dx.doi.org/10.1161/01.CIR.0000072771.11429.83[Crossref]
• [18] Geisler T., Langer H., Wydymus M., Gohring K., Zurn C.H., Bigalke B., et al., Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation., Eur. Heart. J., 2006, 27, 2420–25 http://dx.doi.org/10.1093/eurheartj/ehl275[Crossref]
• [19] Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., et al., High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome., J. Thromb. Haemost., 2006, 4, 542–49 http://dx.doi.org/10.1111/j.1538-7836.2005.01751.x[Crossref]
• [20] Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D., Platelet function monitoring in patients with coronary artery disease., J. Am. Coll. Cardiol., 2007, 19, 1822–34 http://dx.doi.org/10.1016/j.jacc.2007.07.051[Crossref]
• [21] Michelson A.D., Platelet function testing in cardiovascular diseases., Circulation., 2004, 110, 489–93 http://dx.doi.org/10.1161/01.CIR.0000147228.29325.F9[Crossref]
• [22] Ingerman C., Smith J.B., Silver M.J., Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP and an accumulation of radiolabeled platelets., J. Lab. Clin. Med., 1983, 101, 44–52
• [23] Geiger J., Brich J., Hönig-Liedl P., Eigenthaler M., Schanzenbächer P., Herbert J.M., et al., Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel., Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2007–11 [Crossref]
• [24] Gori A.M., Marcucci R., Migliorini A., Valenti R., Moschi G., Paniccia R., et al., Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents., J. Am. Coll. Cardiol., 2008, 52, 734–39 http://dx.doi.org/10.1016/j.jacc.2008.05.032[Crossref]
• [25] Campo G., Valgimigli M., Gemmati D., Percoco G., Catozzi L., Frangione A., et al., Poor responsiveness to clopidogrel: drug-specific or class effect mechanism?, J. Am. Coll. Cardiol., 2007, 12, 1132–37 http://dx.doi.org/10.1016/j.jacc.2007.04.092[Crossref]
• [26] Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al., TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes., N. Engl. J. Med., 2007, 357, 2001–15 http://dx.doi.org/10.1056/NEJMoa0706482[Crossref]

Identifiers

DOI

10.2478/s11536-009-0007-8